Duplex inactivated vaccine of porcine circovirus type 2 and porcine mycoplasma hyopneumoniae and preparation method of duplex inactivated vaccine

A dual inactivated vaccine and mycoplasma pneumonia technology, applied in virus/bacteriophage, biochemical equipment and methods, antiviral agents, etc., to reduce stress, avoid immune paralysis, and avoid immune failure

Active Publication Date: 2013-08-28
兆丰华生物科技(南京)有限公司 +3
View PDF5 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At this stage, there is no dual inactivated vaccine of porcine circovirus type 2 and porcine circovirus type 2 on the market, so a vaccine that can prevent mixed infection of porcine mycoplasma pneumonia and porcine circovirus type 2 is also essential

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Duplex inactivated vaccine of porcine circovirus type 2 and porcine mycoplasma hyopneumoniae and preparation method of duplex inactivated vaccine
  • Duplex inactivated vaccine of porcine circovirus type 2 and porcine mycoplasma hyopneumoniae and preparation method of duplex inactivated vaccine
  • Duplex inactivated vaccine of porcine circovirus type 2 and porcine mycoplasma hyopneumoniae and preparation method of duplex inactivated vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] The preparation of embodiment 1 swine mycoplasma pneumonia inactivated vaccine

[0040] (1) Procedure for multiplying Mycoplasma hyopneumoniae

[0041] ① Propagation of Mycoplasma hyopneumoniae: inoculate Mycoplasma hyopneumoniae liquid medium (recipe see CN201110001231.0) with Mycoplasma hyopneumoniae at a ratio of 10% (V / V), culture at 37°C for 9 days, the color of the medium turns yellow and the pH drops. Harvest the bacterium liquid at 6.8 o'clock, and the amount of the harvested bacterium liquid is 50000ml. The live bacterial titer of Mycoplasma hyopneumoniae (DJ-166 strain) was 10 9 CCU / ml.

[0042] ② Concentration and purification of Mycoplasma hyopneumoniae: Concentrate the Mycoplasma hyopneumoniae liquid with an ultrafiltration membrane system to make the concentration of Mycoplasma hyopneumoniae liquid reach 10 11 ~10 12 CCU / ml, the amount of concentrated bacterial solution is 7600ml. Centrifuge the above bacterial solution at low speed and discard the prec...

Embodiment 2

[0057] Example 2 Protective test of different virulent challenge after immunizing pigs with swine mycoplasma pneumonia inactivated vaccine (DJ-166 strain)

[0058] In order to evaluate the immune effect of the inactivated Mycoplasma pneumoniae vaccine (DJ-166 strain), the pigs were immunized with the vaccine and challenged with strong virus strains from different sources, so as to investigate the protective effect of the vaccine against the strong virus prevailing in different places.

[0059] Use 15 Fujian black pigs 14-20 days old with negative serum antibody to Mycoplasma hyopneumoniae, inject 2.0ml of mycoplasma pneumoniae inactivated vaccine (DJ-166 strain) intramuscularly into each head, and set up 15 challenge control pigs at the same time, inject intramuscularly into each head Normal saline 2.0ml, isolated under the same conditions. Twenty-eight days after immunization, the immunization group and the challenge control group were randomly divided into 3 groups with 5 an...

Embodiment 3

[0065] Example 3 Comparative research test on the immune efficacy of porcine mycoplasma pneumonia inactivated vaccine and similar products

[0066] The inactivated vaccine for Mycoplasma pneumoniae in swine (strain DJ-166) prepared according to Example 1 was compared with the inactivated vaccine for Mycoplasma pneumoniae in swine (batch number A063229) produced by Pfizer in the United States in terms of immune efficacy and immune generation period.

[0067] Vaccine efficacy test: 15 Fujian black pigs 14-20 days old with negative serum antibodies to Mycoplasma hyopneumoniae were divided into 3 groups, each head of the first group was intramuscularly injected with 2.0ml of mycoplasma pneumonia inactivated vaccine (DJ-166 strain), and the first group Each head of the 2 groups was intramuscularly injected with 2.0ml of inactivated vaccine against mycoplasma pneumonia produced by Pfizer of the United States, and the third group was the challenge control group. Breeding in isolation...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a duplex inactivated vaccine of porcine circovirus type 2 and porcine mycoplasma hyopneumoniae. The duplex inactivated vaccine comprises an inactivated porcine circovirus type 2 antigen, inactivated mycoplasma hyopneumoniae and an oil adjuvant, wherein the mycoplasma hyopneumoniae is of DJ-166 strains and has the preservation number No.4545 in China general microbiological culture collection center. The porcine duplex inactivated vaccine has an obvious technical effect on prevention of porcine circovirus type 2 and porcine mycoplasma hyopneumoniae. The safety test shows that the single dosage of the vaccine, the repetition of the single dosage and an overdosing amount of inoculation against test animals are safe, the test animals have normal body temperature and mental states, and the clinical symptoms are avoided; and the efficacy test shows that the duplex inactivated vaccine has a good protection function of virulently attacking the porcine circovirus type 2 and porcine mycoplasma hyopneumoniae, so that the porcine circovirus type 2 and porcine mycoplasma hyopneumoniae can be effectively prevented.

Description

technical field [0001] The invention belongs to the field of veterinary biological products, and in particular relates to a dual inactivated vaccine of porcine circovirus type 2 and swine mycoplasma pneumoniae and a preparation method thereof. Background technique [0002] Mycoplasma hyopneumoniae of swine (MPS), also known as porcine endemic pneumonia or swine panting disease, is a contagious chronic respiratory disease of pigs caused by Mycoplasma hyopneumoniae (Mhyo), which is widespread worldwide and is a serious It is one of the main pig diseases that endanger the healthy development of pig industry. Although the mortality rate of mycoplasma pneumonia is not high, due to the widespread, long-term and consumption of the epidemic, the feed conversion rate can be reduced, and it can cause a variety of complications in pigs. It is the most important disease that causes economic losses in the pig industry. one. [0003] There are two types of vaccines currently used for im...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61K39/295A61P31/20A61P31/04C12N7/00C12N1/20
Inventor 陈硕王勇王贵华车艳杰赵亚荣汪竹君马腾
Owner 兆丰华生物科技(南京)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap